These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 35008952)
1. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines. Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952 [TBL] [Abstract][Full Text] [Related]
2. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines. Stasiak P; Kaźmierczak D; Jopek K; Nowicki M; Rucinski M; Januchowski R Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628654 [TBL] [Abstract][Full Text] [Related]
3. The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines. Kazmierczak D; Jopek K; Sterzynska K; Ginter-Matuszewska B; Nowicki M; Rucinski M; Januchowski R Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283808 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
5. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. Zou J; Yin F; Wang Q; Zhang W; Li L Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572 [TBL] [Abstract][Full Text] [Related]
6. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179 [TBL] [Abstract][Full Text] [Related]
7. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells. Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582 [TBL] [Abstract][Full Text] [Related]
8. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Liu R; Guo H; Lu S Cancer Med; 2018 Sep; 7(9):4598-4609. PubMed ID: 30019389 [TBL] [Abstract][Full Text] [Related]
9. Role of microRNAs in drug-resistant ovarian cancer cells. Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650 [TBL] [Abstract][Full Text] [Related]
10. miR-509-3p enhances platinum drug sensitivity in ovarian cancer. Niu L; Ni H; Hou Y; Du Q; Li H Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550 [TBL] [Abstract][Full Text] [Related]
11. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278 [TBL] [Abstract][Full Text] [Related]
12. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119 [TBL] [Abstract][Full Text] [Related]
13. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A. Wang J; Liu L J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882 [TBL] [Abstract][Full Text] [Related]
14. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084 [TBL] [Abstract][Full Text] [Related]
15. Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells. Miyamoto M; Sawada K; Nakamura K; Yoshimura A; Ishida K; Kobayashi M; Shimizu A; Yamamoto M; Kodama M; Hashimoto K; Kimura T Sci Rep; 2020 Oct; 10(1):16755. PubMed ID: 33028939 [TBL] [Abstract][Full Text] [Related]
16. Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Januchowski R; Sterzyńska K; Zawierucha P; Ruciński M; Świerczewska M; Partyka M; Bednarek-Rajewska K; Brązert M; Nowicki M; Zabel M; Klejewski A Oncotarget; 2017 Jul; 8(30):49944-49958. PubMed ID: 28611294 [TBL] [Abstract][Full Text] [Related]
17. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer. Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. Hummel R; Sie C; Watson DI; Wang T; Ansar A; Michael MZ; Van der Hoek M; Haier J; Hussey DJ World J Gastroenterol; 2014 Oct; 20(40):14904-12. PubMed ID: 25356050 [TBL] [Abstract][Full Text] [Related]
19. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing. Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363 [TBL] [Abstract][Full Text] [Related]
20. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]